BC
VIVO

Blackhill Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Blackhill Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-450
Closed -$12K – 114
2013
Q4 		$12K Buy
+450
New +$11.1K ﹤0.01% 97

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Blackhill Capital's VIVO Position: Q1 2014 in Review

Blackhill Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2014, closing a stake of 450 shares — an estimated $12K sold.

Blackhill Capital first reported a position in VIVO in Q4 2013 and held it in 1 quarter. The position peaked at $12K in Q4 2013. 166 funds tracked by Wall St. Rank hold VIVO as of Q1 2014.

  • Blackhill Capital reported no remaining Meridian Bioscience Inc position as of Q1 2014 after selling out during the quarter.
  • Blackhill Capital sold 450 Meridian Bioscience Inc shares in Q1 2014, an estimated $12K.
  • Blackhill Capital first reported a position in Meridian Bioscience Inc in Q4 2013 and held it in 1 quarter.
  • Blackhill Capital's Meridian Bioscience Inc position peaked at $12K in Q4 2013.
  • 166 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2014.

Based on Blackhill Capital's 13F filing for Q1 2014, filed 28 Apr 2014.